GlassScriptPhysician profile
Natalie A Workman
NPI 1598096182
$5,840.64
in general payments reported to CMS, 2019-2025
55 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $688 · 2021: $824 · 2022: $757 · 2023: $862 · 2024: $868 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780 · Education: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.03 |
| Education | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $530.33 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $412.68 | 2019-2025 | Imfinzi, Enhertu |
| Janssen Biotech, INC. | $384.21 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Pfizer INC. | $356.40 | 2019-2025 | |
| Daiichi Sankyo INC. | $311.66 | 2021-2025 | Enhertu, Injectafer |
| Genzyme Corporation | $251.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $237.30 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $224.26 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $220.57 | 2019-2023 | Imbruvica |
| Amgen INC. | $208.99 | 2020-2023 | Nplate, Xgeva, Vectibix |
| Genentech USA, INC. | $190.67 | 2019-2025 | Tecentriq, Polivy, Columvi |
| Regeneron Healthcare Solutions, INC. | $178.90 | 2022-2025 | Libtayo |
| Astellas Pharma US INC | $153.02 | 2019-2024 | Padcev |
| Lilly USA, LLC | $146.57 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $138.19 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $123.08 | 2022-2025 | Fotivda |
| Abbvie INC. | $118.00 | 2019-2024 | Venclexta |
| Emd Serono, INC. | $109.35 | 2019-2024 | Bavencio |
| Glaxosmithkline, LLC. | $106.80 | 2020-2025 | Zejula, Jemperli |
| Seagen INC. | $104.82 | 2021-2023 | Padcev |
| Celgene Corporation | $89.20 | 2022-2024 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $84.70 | 2019-2025 | Gavreto, Tavalisse, Rezlidhia |
| Bayer Healthcare Pharmaceuticals INC. | $72.82 | 2019-2021 | |
| Coherus Oncology, INC. | $69.68 | 2021-2025 | Loqtorzi |
| Exelixis INC. | $66.64 | 2020-2024 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $65.90 | 2020-2023 | Iclusig |
| Sobi, INC | $65.27 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $62.78 | 2020-2025 | |
| Eisai INC. | $58.12 | 2019-2022 | |
| Kyowa Kirin, INC. | $52.61 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $51.83 | 2023-2024 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $50.21 | 2021-2024 | Qinlock |
| Genmab U.S., INC. | $49.34 | 2023-2024 | Epkinly, Tivdak |
| Gilead Sciences, INC. | $42.79 | 2022-2024 | |
| Mirati Therapeutics, INC. | $42.36 | 2023 | Krazati |
| Myovant Sciences INC. | $41.33 | 2021-2022 | |
| Taiho Oncology, INC. | $35.29 | 2021-2024 | |
| Karyopharm Therapeutics INC. | $30.14 | 2024 | Xpovio |
| Kite Pharma, INC. | $28.42 | 2020-2023 | |
| Cti Biopharma Corp. | $23.94 | 2023 | Vonjo |
| Tempus Ai, INC | $23.78 | 2025 | Xt Cdx |
| Clovis Oncology, INC. | $20.36 | 2019 | |
| Morphosys, US INC. | $20.15 | 2023 | Monjuvi |
| Recordati_rare_diseases_inc. | $19.08 | 2023 | Sylvant |
| Apellis Pharmaceuticals, INC. | $18.73 | 2024 | Empaveli |
| Syndax Pharmaceuticals, INC. | $17.98 | 2025 | Revuforj |
| Pharmacosmos Therapeutics INC. | $15.93 | 2025 | Monoferric |
| Agios Pharmaceuticals, INC. | $15.36 | 2020 | |
| G1 Therapeutics, INC. | $15.27 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $14.63 | 2021 | |
| Dova Pharmaceuticals | $14.43 | 2021 | |
| Aurobindo Pharma USA, INC. | $14.38 | 2019 | |
| Springworks Therapeutics, INC. | $13.77 | 2024 | Ogsiveo |
| Servier Pharmaceuticals LLC | $13.69 | 2021 | |
| Pharmaessentia USA Corporation | $12.72 | 2023 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.